XML 28 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss) - USD ($)
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Expenses      
Sales and marketing $ 483,530 $ 80,603 $ 7,029
Research and development 342,168 954,593 1,608,895
General and administrative 1,209,847 557,904 366,435
Professional and consulting fees 1,623,209 1,158,484 1,252,510
Loss before other items (3,658,754) (2,751,584) (3,234,869)
Other items      
Other income 879,344
Depreciation (4,268) (240)
Interest income 95,787 2,134 1,554
Interest expense (9,270) (52,941)
Foreign exchange (loss)/gain (7,317) (2,695) 26,912
Listing expense (41,481,605)
Transaction expense (2,461,025)
Gain on debt settlement 281,500
Fair value gain/(loss) on convertible note 3,357,628 (5,157,397)
Fair value gain/(loss) on warrant liability 694,516 (306,250)
Fair value gain/(loss) on promissory notes 705,565 (108,288)
Fair value loss on warrant exchange (185,064)
Fair value gain on investment in Psyence Labs Ltd 22,967
NET INCOME/(LOSS) 1,011,790 (51,159,048) (3,206,403)
Other comprehensive income/(loss)      
Foreign exchange gain/(loss) on translation (9,859) 3,715 (89,828)
Other comprehensive income 191,982
TOTAL COMPREHENSIVE INCOME/(LOSS) $ 1,001,931 $ (50,963,351) $ (3,296,231)
Income/(Loss) per share - basic (in Dollars per share) $ 5.24 $ (4,674.25) $ (394.06)
Income/(Loss) per share - diluted (in Dollars per share) $ 5.24 $ (4,674.25) $ (394.06)
Weighted average number of outstanding shares - basic (in Shares) 193,043 10,903 8,365
Weighted average number of outstanding shares - diluted (in Shares) 193,043 10,903 8,365